TABLE 2

Comparison of basal and norepinephrine-induced lipolysis between omental and subcutaneous preadipocytes differentiated for 16 days in the presence or absence of rosiglitazone

Glycerol release−Rosiglitazone
+Rosiglitazone
OMSCP (OM vs. SC)OMSCP (OM vs. SC)
A) μmol/(1 × 3 h)
 Basal1.35 ± 0.260.87 ± 0.19NS1.98 ± 0.42*1.54 ± 0.23*NS
 NE 10−7 mol/l3.75 ± 0.980.73 ± 0.14<0.0522.97 ± 8.37*2.90 ± 0.78*<0.05
 NE 10−5 mol/l3.17 ± 0.601.20 ± 0.22<0.0523.16 ± 7.23*2.91 ± 0.31*<0.05
B) μmol/(g protein ×     3 h)
 Basal16.09 ± 3.329.63 ± 2.07NS15.51 ± 14.6016.49 ± 3.24NS
 NE 10−7 mol/l43.62 ± 10.717.52 ± 1.18<0.05177.52 ± 59.60*34.14 ± 14.04*<0.05
 NE 10−5 mol/l39.75 ± 9.9712.80 ± 3.01<0.05181.24 ± 54.13*31.35 ± 4.77*<0.05
C) nmol/(mU GPDH ×     μg protein × 3 h)
 BasalNDND14.23 ± 5.789.00 ± 1.15NS
 NE 10−7 mol/lNDND114.32 ± 34.3317.62 ± 3.53<0.05
 NE 10−5 mol/lNDND104.88 ± 24.3618.95 ± 3.39<0.05
  • Data are means ± SE. Glycerol release is expressed as A) absolute concentration released into the medium, B) A corrected for differences in total cell amount expressed as amount of total protein, and C) A corrected for preadipocyte differentiation expressed as GPDH activity. Glycerol release was statistically compared between omental (OM) and subcutaneous (SC) preadipocytes and between cells differentiated with (+rosiglitazone) or without rosiglitazone (−rosiglitazone) (

  • *

    * P < 0.05). NS, nonsignificant. ND, GPDH activity was below the detection limit. Number of experiments = 7.